Good pick up. I am sure they certainly would have gone for BT designation as a significant value add for commercial discussions. BT needs to have shown clinical benefit on serious symptoms (check), significant unmet need (check), no later than end of P2 (check).
So we are lined up for BT designation, FDA approval on P3 and agreed RBSQ end point and a deal with big pharma. The next couple of months are going to be significant - no room for a negative ann, not that I am expecting one.
NEU Price at posting:
6.8¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)